14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ARCT vs TAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–3 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: ARCT 1 – 5 TAK
Matrix Metrics: ARCT 3 – 6 TAK
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Arcturus Therapeutics Holdings Inc. (ARCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ARCT carries a Unified Composite Score of 57.7/100 (HOLD) at $8.61 (2.5x Forward P/E, -311.2% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).
Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. TAK 48.0/100 HOLD), TAK captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (16.6% vs. -311.2% operating margin) and revenue trajectory (+6.7% vs. +6.7% YoY).
Technical & Structure Timing Caution: ARCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARCT vs TAK. Trailing 12-month operating profitability (ARCT -311.2% vs TAK 16.6%) and valuation multiples (ARCT 2.5x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $241.0M market capitalization and -311.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
TAK Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
Investor FAQ ARCT vs TAK Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Arcturus Therapeutics Holdings Inc. (ARCT) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ARCT carries a Unified Composite Score of 57.7/100 (HOLD) at $8.61 (2.5x Forward P/E, -311.2% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. TAK 48.0/100 HOLD), TAK captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (16.6% vs. -311.2% operating margin) and revenue trajectory (+6.7% vs. +6.7% YoY). Technical & Structure Timing Caution: ARCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1); meanwhile TAK trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TAK leads the Growth & Scale pillar: ARCT posts +6.7% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (N/A gross margin, -311.2% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, ARCT generates $31M in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, ARCT deploys N/A (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.
ARCT screens cheaper on headline valuation multiples. ARCT trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARCT (-44.4% ROE) versus TAK (0.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ARCT carries 96.3% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.03β · 127% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.